J. A. Elias

This study shows CHI3L1 is induced by EGFR activation in NSCLC and promotes EGFR signaling, with anti-CHI3L1 antibodies reversing TKI resistance and inhibiting metastasis.

This study shows CHI3L1 promotes melanoma lung metastasis by inhibiting T cell co-stimulators and stimulating CTLA-4/B7 axis, with combined anti-CHI3L1 and anti-CTLA-4 antibodies showing synergistic antitumor effects.

This study shows that targeting CHI3L1 inhibits SARS-CoV-2 variants' infection of epithelial cells, suggesting it as a universal therapeutic target.

This study shows Chi3l1 modulates glioma stem cell states by altering transcription factor activity and cell state transitions, and demonstrates anti-Chi3l1 antibody treatment inhibits glioblastoma growth.

This study identifies dysregulated myogenesis and autophagy in COPD-induced muscle dysfunction and shows that autophagy stimulation can improve satellite cell function and myogenesis.

This study identifies Chi3l1 as a key mediator of acetaminophen-induced liver injury by promoting hepatic platelet recruitment through the CD44 axis.

This study identifies Kasugamycin as a novel CHIT1 inhibitor with strong antifibrotic effects in pulmonary fibrosis models.

This study shows Chi3l1 promotes PD-L1 and other immune checkpoint inhibitors in melanoma, suggesting combined targeting of Chi3l1 and PD-1-PD-L1 as a therapeutic strategy for pulmonary metastasis.

This study identifies CHI3L1 as a key mediator of aging-related severity in COVID-19 by stimulating ACE2 and SPP expression, and shows it is a therapeutic target.

This study shows MEK inhibitors reduce ACE2 and inflammatory cytokines, enhance NK cell activity, and block SARS-CoV-2 pseudovirus infection in human cells.